These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 28665894)

  • 1. Non-HLA Antibodies Impact on C4d Staining, Stellate Cell Activation and Fibrosis in Liver Allografts.
    OʼLeary JG; Demetris AJ; Philippe A; Freeman R; Cai J; Heidecke H; Smith C; Hart B; Jennings LW; Catar R; Everly M; Klintmalm GB; Dragun D
    Transplantation; 2017 Oct; 101(10):2399-2409. PubMed ID: 28665894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of preformed donor-specific antibodies and C4d on early liver allograft function.
    Perera MT; Silva MA; Murphy N; Briggs D; Mirza DF; Neil DA
    Scand J Gastroenterol; 2013 Dec; 48(12):1444-51. PubMed ID: 24131305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donor-Specific Anti-HLA Antibodies and Endothelial C4d Deposition-Association With Chronic Liver Allograft Failure.
    Iacob S; Cicinnati VR; Lindemann M; Heinemann FM; Radtke A; Kaiser GM; Kabar I; Schmidt HH; Baba HA; Beckebaum S
    Transplantation; 2015 Sep; 99(9):1869-75. PubMed ID: 25706274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 3-Center Study Reveals New Insights Into the Impact of Non-HLA Antibodies on Lung Transplantation Outcome.
    Reinsmoen NL; Mirocha J; Ensor CR; Marrari M; Chaux G; Levine DJ; Zhang X; Zeevi A
    Transplantation; 2017 Jun; 101(6):1215-1221. PubMed ID: 27973391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretransplant angiotensin II type 1-receptor antibodies are a risk factor for earlier detection of de novo HLA donor-specific antibodies.
    Cuevas E; Arreola-Guerra JM; Hernández-Méndez EA; Salcedo I; Castelán N; Uribe-Uribe NO; Vilatobá M; Contreras-Saldívar AG; Sánchez-Cedillo AI; Ramírez JB; de Rungs D; Granados J; Morales-Buenrostro LE; Alberú J
    Nephrol Dial Transplant; 2016 Oct; 31(10):1738-45. PubMed ID: 27220757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preformed complement-activating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts.
    Lawrence C; Willicombe M; Brookes PA; Santos-Nunez E; Bajaj R; Cook T; Roufosse C; Taube D; Warrens AN
    Transplantation; 2013 Jan; 95(2):341-6. PubMed ID: 23197178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies.
    Haas M; Mirocha J; Reinsmoen NL; Vo AA; Choi J; Kahwaji JM; Peng A; Villicana R; Jordan SC
    Kidney Int; 2017 Mar; 91(3):729-737. PubMed ID: 28104301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sinusoidal C4d deposits in liver allografts indicate an antibody-mediated response: diagnostic considerations in the evaluation of liver allografts.
    Kozlowski T; Andreoni K; Schmitz J; Hayashi PH; Nickeleit V
    Liver Transpl; 2012 Jun; 18(6):641-58. PubMed ID: 22298469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor-specific alloantibodies are associated with fibrosis progression after liver transplantation in hepatitis C virus-infected patients.
    O'Leary JG; Kaneku H; Jennings L; Susskind BM; Terasaki PI; Klintmalm GB
    Liver Transpl; 2014 Jun; 20(6):655-63. PubMed ID: 24678017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical relevance of preformed C4d-fixing and non-C4d-fixing HLA single antigen reactivity in renal allograft recipients.
    Wahrmann M; Bartel G; Exner M; Regele H; Körmöczi GF; Fischer GF; Böhmig GA
    Transpl Int; 2009 Oct; 22(10):982-9. PubMed ID: 19619171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective Monitoring of Donor-specific Anti-HLA Antibodies After Intestine/Multivisceral Transplantation: Significance of De Novo Antibodies.
    Kubal C; Mangus R; Saxena R; Lobashevsky A; Higgins N; Fridell J; Tector AJ
    Transplantation; 2015 Aug; 99(8):e49-56. PubMed ID: 25769071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of Complement-binding Donor-specific Antibodies, Not IgG-antibody Strength Nor C4d Status, at Antibody-mediated Rejection Diagnosis Is an Independent Predictor of Kidney Graft Failure.
    Malheiro J; Santos S; Tafulo S; Dias L; Martins S; Fonseca I; Almeida M; Pedroso S; Beirão I; Castro-Henriques A; Cabrita A
    Transplantation; 2018 Nov; 102(11):1943-1954. PubMed ID: 29757900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation.
    Musat AI; Agni RM; Wai PY; Pirsch JD; Lorentzen DF; Powell A; Leverson GE; Bellingham JM; Fernandez LA; Foley DP; Mezrich JD; D'Alessandro AM; Lucey MR
    Am J Transplant; 2011 Mar; 11(3):500-10. PubMed ID: 21342448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased erythrocyte C4D is associated with known alloantibody and autoantibody markers of antibody-mediated rejection in human lung transplant recipients.
    Golocheikine A; Nath DS; Basha HI; Saini D; Phelan D; Aloush A; Trulock EP; Hachem RR; Patterson GA; Ahearn JM; Mohanakumar T
    J Heart Lung Transplant; 2010 Apr; 29(4):410-6. PubMed ID: 20022265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-HLA Antibodies May Accelerate Immune Responses After Intestinal and Multivisceral Transplantation.
    Gerlach UA; Lachmann N; Ranucci G; Sawitzki B; Schoenemann C; Pratschke J; Dragun D; Pascher A
    Transplantation; 2017 Jan; 101(1):141-149. PubMed ID: 27495766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis.
    Gosset C; Viglietti D; Rabant M; Vérine J; Aubert O; Glotz D; Legendre C; Taupin JL; Duong Van-Huyen JP; Loupy A; Lefaucheur C
    Kidney Int; 2017 Sep; 92(3):729-742. PubMed ID: 28554738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preformed and de novo DSA are associated with T-cell-mediated rejection in pediatric liver transplant recipients requiring clinically indicated liver biopsy.
    Schluckebier D; Cousin VL; Petit LM; Belli D; Wildhaber B; Rougemont AL; Villard J; Ferrari-Lacraz S; McLin VA
    Pediatr Transplant; 2020 Feb; 24(1):e13611. PubMed ID: 31682057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of complement split product C4d in ABO-compatible liver allograft: diagnosing utility in acute antibody mediated rejection.
    Ali S; Ormsby A; Shah V; Segovia MC; Kantz KL; Skorupski S; Eisenbrey AB; Mahan M; Huang MA
    Transpl Immunol; 2012 Jan; 26(1):62-9. PubMed ID: 21907804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance and implications of capillaritis during acute rejection of kidney allografts.
    Cosio FG; Lager DJ; Lorenz EC; Amer H; Gloor JM; Stegall MD
    Transplantation; 2010 May; 89(9):1088-94. PubMed ID: 20216485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. De novo donor-specific anti-HLA antibodies mediated rejection in liver-transplant patients.
    Del Bello A; Congy-Jolivet N; Danjoux M; Muscari F; Lavayssière L; Esposito L; Cardeau-Desangles I; Guitard J; Dörr G; Milongo D; Suc B; Duffas JP; Alric L; Bureau C; Guilbeau-Frugier C; Rostaing L; Kamar N
    Transpl Int; 2015 Dec; 28(12):1371-82. PubMed ID: 26303035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.